CNS Pharmaceuticals, Inc.
CNSP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $23 | $237,173 | $162,756 | $891,978 |
| - Cash | $6 | $1 | $10 | $5 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $17 | $237,172 | $162,747 | $891,973 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$15 | -$19 | -$15 | -$14 |
| % Margin | – | – | – | – |
| Net Income | -$15 | -$19 | -$15 | -$14 |
| % Margin | – | – | – | – |
| EPS Diluted | -38.87 | -60 | -134.64 | -6.36 |
| % Growth | 35.2% | 55.4% | -2,017% | – |
| Operating Cash Flow | -$17 | -$14 | -$11 | -$14 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$17 | -$14 | -$11 | -$14 |